News About: Pharm. Industry
Samsung Bioepis starts to develop new drug for acute pancreatitis
Samsung Bioepis(CEO/President Han-Seung Ko) will start to develop new drugs for acute pancreatitis.
Samsung Bioepis said they would conduct a Phase I clinical trial for an acute pancreatitis therapy candidate(project...
Will Valsartan incident largely impact on medium-sized pharmas?
The antihypertensive Valsartan incident has been spread widely. The pharmaceutical industry thinks, particularly, the incident will not only become a problem with Chinese Valsartan ingredients but impact the entire Ch...
Celltrion makes KRW 263.4 billion sales in 2nd quarter
On the 8th, Celltrion gave a notice about the company’s 2018 2nd quarter consolidated business performance that they had a 7% increase to KRW 263.4 billion sales, but a 21.7% decrease to KRW 108.2 billion operating pr...
Samsung Group, “We’ll make biopharmaceutical field as the next semiconductor business”
Samsung Group will start to aggressively invest funds to make the biologic field to the next semiconductor business.
On the 8th, Samsung announced plans to invest total KRW 180 trillion for the next 3 years to contin...
Celltrion starts Phase I and Phase III clinical trials for Humira biosimilar
Celltrion recently announced that they made a clinical trial application for ‘CT-P17,’ a biosimilar referencing the rheumatoid arthritis therapy ‘Humira(generic name: adalimumab),’ to the U.K. Medicines and Healthcare...
Kolon Life Science’s Invossa Inj to achieve 1,500 procedures
Kolon Life Science(CEO Woo-Seok Lee) announced they acquired approval of Invossa on July 2017, started to sell the product on November and achieved more than 1,500 procedures to July 2018 for 9 months.
According to t...
Medytox, Hugel and Chong Kun Dang Holdings ranked top in market value
Medytox, Hugel, and Chong Kun Dang Holdings were ranked higher in market value among other small and medium biopharmaceutical companies listed in Asian securities markets.
According to the ‘Forbes Asian Small and Med...
Daewoong finishes resubmitting documents for Nabota to FDA
Daewoong Pharmaceutical’s botulinum toxin ‘Nabota’ has taken the last step to enter the U.S. market.
Daewoong Pharmaceutical(CEO Seung-Ho Jeon) announced on the 2nd that they turned in revised documents to the U.S. F...
70 Korean pharmas including Yuhan Corporation participate in ‘CPhI Worldwide 2018’
About 70 Korean pharmaceutical companies will participated in the world’s largest pharmaceutical conference held in Madrid, Spain on the coming 10th ‘CPhI Worldwide 2018’ and start to pioneer new exporting markets.
T...
Dong Wha Pharm’s first step to enter global market
Dong Wha Pharm, the oldest Korean pharmaceutical company with 121 years of history, have been active in expanding its new drug business to other countries, strengthen its open innovation profile and starting more new ...
